FDA approves Alembic’s generic Wellbutrin
The Food and Drug Administration has approved Alembic Pharmaceuticals’ generic Wellbutrin (bupropion HCL) tablets. The drug is indicated to treat major depressive disorder.
Alembic’s generic Wellbutrin will be available in 75- and 100-mg dosage strengths. The product’s market size for the 12 months ended December 2017 was $37 million, according to IQVIA data.
Alembic’s generic Wellbutrin will be available in 75- and 100-mg dosage strengths. The product’s market size for the 12 months ended December 2017 was $37 million, according to IQVIA data.